Home > Boards > US OTC > Medical - Drugs > Tenax Therapeutics, Inc. (TENX)

Well it’s one of the risks noted in

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
RisingMT Member Profile
 
Followed By 4
Posts 633
Boards Moderated 0
Alias Born 03/17/17
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2019 4:34:25 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2019 4:54:55 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/22/2019 4:31:34 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/19/2019 4:32:33 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/18/2019 4:34:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/18/2019 4:34:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/18/2019 4:33:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/18/2019 4:33:39 PM
Annual Report (10-k) Edgar (US Regulatory) - 4/1/2019 4:33:58 PM
Tenax Therapeutics Enrolls First Patient for Phase 2 Pulmonary Hypertension Clinical Trial Business Wire - 3/11/2019 8:30:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2019 11:37:54 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/12/2019 5:36:33 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/5/2019 2:08:30 PM
Tenax Therapeutics to Present at 2019 BIO CEO & Investor Conference Business Wire - 2/4/2019 8:30:00 AM
Tenax Therapeutics to Present at Biotech Showcase Investor Conference Business Wire - 1/4/2019 8:30:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 12/14/2018 3:45:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/11/2018 4:07:59 PM
Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering Business Wire - 12/11/2018 4:00:00 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 12/10/2018 6:01:46 AM
Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) Edgar (US Regulatory) - 12/7/2018 5:12:47 PM
Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering Business Wire - 12/7/2018 1:02:00 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 12/6/2018 8:33:10 AM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 12/3/2018 5:28:07 PM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 11/20/2018 5:06:34 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 11/20/2018 4:33:39 PM
RisingMT   Monday, 04/08/19 11:52:06 AM
Re: A deleted message
Post # of 7816 
Well it’s one of the risks noted in the 10K. Have you read it?

With limited funding and no other trials in the works, Tenax is relying on the success of levosimendan. Additionally, they’ll need to be successful at commercializing it in the case that it is approved. They won’t be able to fund another trial.

It’s not blatant negativity as I’m stating what’s in the 10K

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist